Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Guler goal gives muchLewis Morgan's goal helps Red Bulls play Whitecaps to 1'Hideous' newbuild house with a 'kitchen floor' outside is slammed for crucial design flawChinese GP witnesses Shanghai's racing evolutionA Hindu festival in southwestern Pakistan brings a mountainous region to lifeJets go offense, offense and more offense around Aaron Rodgers throughout the NFL draftChants of ‘shame on you’ greet guests at White House Correspondents’ dinnerChina's top political advisory body concludes standing committee sessionCan't sleep? Ditch the duvet and just snuggle under a heavy blanketAfter officer warns campaigner for being 'openly Jewish'... Met Police are so cowed by the anti
3.2145s , 6505.0078125 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Worldly Web news portal